A practical reference on dihexa: what it is, how it behaves, what the literature reports, and where the honest uncertainties sit.
Reviewed 2026-03-31. Anything still debated is marked as such rather than presented as settled.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
The compound has been examined in animal models for effects on learning, memory, and synaptic connectivity. Some reports describe increased dendritic spine density and improved performance on certain behavioral tasks after administration in rodents. These findings are often cited in discussions of nootropic research peptides, but replication across independent laboratories remains limited. The absence of published phase 1 or phase 2 clinical trial data makes it difficult to assess safety, effective routes, or long-term outcomes in humans. Consequently, claims about cognitive benefits in people remain speculative.
Regulatory status differs by country, but dihexa is generally not approved as a therapeutic product. It is often sold as a research chemical, which means purity, labeling, and handling fall outside pharmaceutical drug standards. Some jurisdictions restrict the sale of peptides intended for human consumption. Researchers and suppliers may therefore face different legal requirements depending on location. Import rules and customs enforcement can also affect how such compounds move across borders.
Human safety data are sparse. No widely accepted dosing regimen, long-term safety profile, or clinical efficacy endpoint has been established. Published animal results can suggest directions for further study, but species differences and study design limit direct translation. Open questions include bioavailability, blood-brain barrier penetration, metabolism, and whether observed effects arise from a single target or multiple pathways. Replication across independent laboratories remains an important benchmark for evaluating the strength of preclinical claims.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
Discussion in the literature often separates direct receptor activation from downstream growth-factor modulation. Dihexa is not simply an angiotensin receptor blocker or a classic nootropic drug. Its proposed action may depend on endogenous HGF levels, which vary by tissue and physiological state. Questions remain about brain penetration, metabolic stability, and active metabolites. Reviews note that mechanistic claims should be treated as hypotheses until supported by independent studies. That distinction is important when interpreting promotional claims or early laboratory findings.
The leading hypothesis for dihexa centers on hepatocyte growth factor (HGF) and its receptor, c-Met. In cell-based assays, dihexa has been reported to potentiate HGF-dependent signaling. That pathway influences cell growth, survival, and motility. Because c-Met signaling is widespread, the proposed mechanism is broad rather than specific to neurons. The exact binding site and stoichiometry remain areas of active investigation, and independent replication is limited. This uncertainty limits firm conclusions about how the compound acts in living organisms.
Animal studies have examined dihexa in models of cognitive impairment, synaptic plasticity, and memory. Some reports describe improved performance on maze or avoidance tasks after administration. These findings are preclinical and often involve small samples, varied routes, and differing formulations. Results in rodents do not establish effects in humans. The absence of published randomized controlled trials in people is a major gap in the evidence base. Observational reports and user accounts do not substitute for controlled clinical data.
Regulatory status varies by country, and dihexa is not widely approved as a medicine. In many jurisdictions it is treated as a research chemical, which limits its legal sale, possession, and human use. Products marketed online may lack verified purity or identity, and labels can be inaccurate. Researchers typically source material from suppliers that provide analytical documentation and follow institutional safety rules. Open questions remain about long-term stability, metabolite formation, and human pharmacokinetics.
Dihexa is typically supplied as a lyophilized powder for laboratory research. Lyophilization removes water and improves stability during transport and storage. The solid is commonly stored at -20 °C or lower, desiccated, and protected from light. Repeated freeze-thaw cycles and exposure to moisture can degrade peptides, so aliquoting and sealed containers are standard practice in most laboratory settings. These handling measures apply to research-grade material and do not imply clinical suitability.
Primary malignant brain tumors (PMBT) and brain metastases have a high impact on patients with both high morbidity and mortality rates. For patients impacted by this, treatment consists primarily of palliative care. However, multimodal therapy using intra-CSF chemotherapy has shown promise in overt leukemic or lymphomatous meningeosis and primary CNS lymphomas. This form of chemotherapy is less toxic while maintaining similar efficacy to cranial irradiation, by preventing the infiltration and proliferation of leukemic and tumor cells into the leptomeninges. In a 2019 study, autologous non-genetically modified adipose-derived stromal vascular fraction (ADSVF) was injected into 24 patients using an ICV injection procedure. Seven other patients were injected through ventriculoperitoneal shunts. These seven patients were being treated for varying neurodegenerative disorders including Alzheimer's disease (AD), amyotrophic lateral sclerosis (ALS), progressive multiple sclerosis (MS-P), Parkinson's, spinal cord injury, traumatic brain injury, and stroke. A total of 113 injections were performed on the 31 patients, with one patient having up to 15 injections over three years. Follow-up was conducted for each participant, with varying follow-up times. One patient developed an infection from their implant, and four patients required hospitalization after their injections. Overall, the results indicate that ICV injections, both single and repeat, are safe.
=== Other concerns === A potentially significant problem following bisulfite treatment is incomplete desulfonation of pyrimidine residues due to inadequate alkalization of the solution. This may inhibit some DNA polymerases, rendering subsequent PCR difficult. However, this situation can be avoided by monitoring the pH of the solution to ensure that desulfonation will be complete. A final concern is that bisulfite treatment greatly reduces the level of complexity in the sample, which can be problematic if multiple PCR reactions are to be performed (2006). Primer design is more difficult, and inappropriate cross-hybridization is more frequent.
=== Shake lotion === A shake lotion is a mixture that separates into two or three parts over time. Frequently, an oil mixed with a water-based solution needs to be shaken into suspension before use and includes the instructions: "Shake well before use".
=== Infection === Infection will complicate healing of surgical wounds and is commonly observed. Most infections are present within the first 30 days after surgery. Surgical wounds can become infected by bacteria, regardless if the bacteria is already present on the patient's skin or if the bacteria is spread to the patient due to contact with infected individuals. Wound infections can be superficial (skin only), deep (muscle and tissue), or spread to the organ or space where the surgery occurred. Recent studies have established that infection after surgery can occur after several years post surgery, and these infection rates are not recorded due to loss in patient follow up, hard to access record of previous surgery, visiting a new surgeon, lack of requirement from national registries etc.
Sources: en.wikipedia.org
== Prevention == Interventions have been recommended to reduce the risk of firearm related injury or death. Various medical organizations in the United States have recommended criminal background checks be required before a person can purchase a gun, and that those convicted for violent crimes be precluded from purchase. They also support safe-storage laws, as well as better mental health care and removal of guns from those at risk of suicide. Physicians are encouraged to counsel patients regarding safe storage and other injury prevention strategies during routine medical care. Keeping guns locked and unloaded is associated with a lower risk of gun related injury or death (including a lower risk of suicide) for all household members. Temporarily removing guns from the home, either voluntarily or by court order (such as with extreme risk protection orders [so called "red flag laws"] in the United States) is recommended for those who are at risk of suicide or violence towards others. Such laws have been associated with a lower risk of suicide using guns in population based studies.
After entering the body, aflatoxins may be metabolized by the liver to a reactive epoxide intermediate or hydroxylated to become the less harmful aflatoxin M1. Aflatoxin poisoning most commonly results from ingestion, but the most toxic aflatoxin compound, B1, can permeate through the skin. The United States Food and Drug Administration (FDA) action levels for aflatoxin present in food or feed is 20 to 300 ppb. The FDA has had occasion to declare both human and pet food recalls as a precautionary measure to prevent exposure. The term "aflatoxin" is derived from the name of the species Aspergillus flavus, in which some of the compounds were first discovered. A new disease was identified with unknown characteristics in England during the 1950s and 1960s, which increased turkey mortality. Later, aflatoxin was recognized in 1960 in England as a causative agent of the mysterious Turkey X disease that causes excessive mortality in turkey poults. Aflatoxins form one of the major groupings of mycotoxins.
=== Legacy === A research center that was planned in the 1970s was opened in 1975 (CBM) in the Autonomous University of Madrid (UAM). After his death, it was named the Centro de Biología Molecular Severo Ochoa. In Leganés, Madrid, a hospital bears his name, as does the Madrid Metro station serving it, Hospital Severo Ochoa. The asteroid 117435 Severochoa is also named in his honor. In 2003, the Spanish General Post Office (Correos) issued a €0,76 postage stamp honoring Ochoa, as one of a pair featuring Spanish medical Nobel Prize winners alongside Santiago Ramón y Cajal. In June 2011, the United States Postal Service issued a stamp honoring him, as part of the American Scientists collection, along with Melvin Calvin, Asa Gray, and Maria Goeppert-Mayer. This was the third volume in the series. The main road in to the tourist resort Benidorm is named Avenida Dr. Severo Ochoa in his honor.
This settlement, boycotted by the PF and rejected internationally, led to multiracial elections and Rhodesia's reconstitution under majority rule as Zimbabwe Rhodesia in June 1979. Muzorewa, the electoral victor, took office as the country's first black prime minister at the head of a coalition cabinet comprising 12 blacks and five whites, including Smith as minister without portfolio. Dismissing Muzorewa as a "neocolonial puppet", ZANLA and ZIPRA continued their armed struggle until December 1979, when Whitehall, Salisbury and the Patriotic Front settled at Lancaster House. Muzorewa's government revoked UDI, thereby ending the country's claim to be independent after 14 years, and dissolved itself. The UK suspended the constitution and vested full executive and legislative powers in a new Governor, Lord Soames, who oversaw a ceasefire and fresh elections during February and March 1980. These were won by ZANU, whose leader Robert Mugabe became Prime Minister when the UK granted independence to Zimbabwe as a republic within the Commonwealth in April 1980. African nationalist politicians continued to cite their opposition to the UDI as a means of legitimising their rule of Zimbabwe into the 21st century. Since it was issued, the UDI has been recounted in scholarly literature, autobiographies of those involved in its creation, and works of fiction.
=== Other types of breast hypertrophy === Only 15% of cases of breast hypertrophy are unrelated to puberty or pregnancy. Other types and causes of breast hypertrophy include idiopathic, drug-induced (e.g., penicillamine, ciclosporin, bucillamine), autoimmunity-associated, tumors, and syndromes. Two case reports of prepubertal breast hypertrophy, both in infants, have been reported.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Published human clinical trial data are limited or absent. Most available evidence comes from laboratory and animal studies. Human safety and efficacy remain unresolved.